Inspire Advisors LLC Makes New $212,000 Investment in Johnson & Johnson (NYSE:JNJ)

Inspire Advisors LLC bought a new position in Johnson & Johnson (NYSE:JNJ) in the 1st quarter, Holdings Channel reports. The firm bought 1,277 shares of the company’s stock, valued at approximately $212,000.

Other hedge funds have also made changes to their positions in the company. Conquis Financial LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth $33,000. Bernard Wealth Management Corp. purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth $36,000. Highline Wealth Partners LLC lifted its stake in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth $49,000. Finally, Capital A Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter worth $50,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on JNJ. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Piper Sandler restated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Raymond James Financial decreased their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research note on Monday, April 14th. Guggenheim reiterated a “neutral” rating and issued a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $174.50.

Johnson & Johnson Stock Up 1.1%

Shares of JNJ stock opened at $168.03 on Wednesday. The stock’s 50-day simple moving average is $156.65 and its 200-day simple moving average is $156.22. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $404.67 billion, a PE ratio of 17.97, a P/E/G ratio of 2.12 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.82 earnings per share. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.